| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2850837 | American Heart Journal | 2011 | 13 Pages |
Abstract
The ATLAS-ACS 2 TIMI 51 is testing the hypothesis that anticoagulation with the oral factor Xa inhibitor rivaroxaban reduces cardiovascular death, MI, and stroke among patients with ACS treated with guideline-based therapies for ACS.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
C. Michael MS, MD, Jessica L. MPH, MD, Paul MD, PhD, Shinya MD, Freek MD, Christoph MD, Alexei MD, Xiang PhD, Nancy MD, Eugene MD,